|  |
| --- |
|  **Article Rating: worst** [ ]  **1** [ ]  **2** [ ]  **3** [ ]  **4** [ ]  **5 best** |
| 1. **Reviewer Name:**
 |
| 1. **Reference (Author, Title):**

**2.1 PubMed ID/Link** |
| 1. **Endpoint: # of Endpoints:**
 |
| **4. Study Classification: Click for menu** |
| **5. Organ/tissue/anatomical region: Click for menu Click for menu** |
| **6. Is radiation dose response analyzed Yes**[ ]  **No**[ ]  **according to developmental status?**  **Comments:**  |
| **7. Delineation of OAR described in paper: Yes**[ ]  **No**[ ]  **Comment:** |
| **8. Primary Cancer Specify:** |
| **9. Eligibility/Exclusion Criteria****9.1 Length of Follow up: Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **9.2 Age at time of childhood cancer diagnosis: Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **9.3 Age at time of evaluation/follow-up: Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **9.4 Calendar period of childhood cancer treatment: Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **9.5 Other: Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **9.6 Comments for items #1-#9:**  |
| **10. Patient Numbers****10.1 Total number of eligible patients:** **10.2 Number of patients analyzed in study:****10.3 Number of events for the relevant endpoint:** **Number or rate (%) of individual endpoint:**  **1.** **2.**  **3.**  |
| **11. Scoring of Side-effects****11.1 Grading system: Click for menu NR**[ ] **11.2 Type of endpoint analyzed: Click for menu NR**[ ] **11.3 If ordinal endpoint is dichotomized, Click for menu NR**[ ]  **threshold grade for calling an event:** **11.4 Method of outcome evaluation****11.4.1 Clinical Assessment** **11.4.1a Physical examination Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.1b Imaging Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.1c Functional Imaging Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.1d Laboratory test Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.1e Other Analytic test Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.2 If 11.4.1. = yes: Corrected for baseline value? Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.3 Self-report only Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.4 Self-report with medical validation Yes**[ ]  **No**[ ]  **NR**[ ] **11.4.5 Registry-linkage based Yes**[ ]  **No**[ ]  **NR**[ ] **11.5 Endpoint classification (check all that apply)**[ ] **Incidence** [ ] **Prevalence** [ ] **Mortality** [ ] **Other -Please specify:****11.6 Method used to adjust for latency: Click for menu** **11.7 Comments for section #11:** |
| **12. Radiation Therapy: Prescribed dose fractionation****12.1 Total Prescribed Dose (Gy): Range:** **Median:** **Min:**  **Max:****12.1.1 Dose per fraction (Gy) Min:**  **Max:****12.1.2 Planned overall time (days) Min:** **Max:****12.2 Dose Prescribed to: Click for menu****12.3 Dose distribution derived from: Click for menu** |
| **13. Radiation therapy: Technical aspects****13.1 Radiation technique: (check all that apply)**[ ] **NR** [ ] **Various** [ ] **Parallel opposing photon fields** [ ] **3D-CRT** **or similar simple arrangements Energy:** [ ]  **KV** [ ] **MV** [ ] **IMRT** [ ] **Brachytherapy** [ ] **Stereotactic or SBRT** [ ] **Particle Therapy** [ ] **Electrons Comment:** **13.2 Heterogeneity correction in dose calc: Click for menu NR**[ ] **13.3 Comments for sections #12 and #13**  |
| **14. Chemotherapy (check all that apply):**[ ] **Not used** [ ] **Unknown** [ ] **Alkylating agents** [ ] **Vinca Alkoids**[ ] **Anthracyclines** [ ] **Epipodophyllotoxins** [ ] **Bleomycin** [ ] **Other**[ ] **Corticosteroids****14.1 Bone Marrow Transplant Yes**[ ]  **No**[ ]  **NR**[ ]  **If Yes, conditioning with TBI Yes**[ ]  **No**[ ]  **NR**[ ] **14.2 Drug and/or BMT effect analyzed in paper Yes**[ ]  **No**[ ]  **NR**[ ]  |
| **15. Data analytic approach (up to 3):**[ ] **Comparison of outcome in two or more groups** [ ] **Use of previously published model/parameters** [ ]  **“Statistical modeling” (Cox, Logistic regression, cumulative incidence)** [ ] **Other method** [ ]  **NR** **Specify:****15.1 Were dose Volume descriptors analyzed? Yes**[ ]  **No**[ ]  **NR**[ ]  **Specify:** **15.2 Dose-volume descriptors found to be significant? Yes**[ ]  **No**[ ]  **NA**[ ] **15.3 Parametric dose-volume modeling? Yes**[ ]  **No**[ ]  **NR**[ ] **15.3.1 Specify Model: Yes**[ ]  **No**[ ]  **Comment:****15.3.2 Specify Model validation: Yes**[ ]  **No**[ ] **15.4 Comments:** |
| **16. Patient Age and Follow-up****16.1 Length of Follow-up (mean, median, and range):****16.2 Age at diagnosis (mean, median and range):****16.3 Age attained at end of follow-up (mean, median, and range):****16.4 Comment:** |
| **17. Variables considered in analysis Significance:****17.1 Age at Diagnosis Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ] **17.2 Attained Age Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ] **17.3 Gender Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ] **17.4 Race Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ] **17.5 Genetic Abnormality Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ] **17.6 Other Yes**[ ]  **No**[ ]  **Yes**[ ]  **No**[ ]  **Specify:****17.7 Co-morbidity Yes**[ ]  **No**[ ]  **Specify:****17.8 Lab tests Yes**[ ]  **No**[ ]  **Specify:****17.9 Other patient related factors considered in the analysis:****17.10 Calendar years of childhood cancer treatment:** |
| **18. Bio-banking or biomarkers assessed: Yes**[ ]  **No**[ ]  |
| **19. Major source of variation in dose-volume histogram:**[ ] **Not clear from paper**[ ] **Inter-individual variation in anatomy and target definition** [ ] **Change in treatment policy over time** [ ] **Varied prescription according to patient/disease factors** [ ] **Randomized allocation to different treatments** [ ] **Minimal variation of dose-volume parameters**  |
| **20 Author’s conclusion:****20.1 Significant volume effect Yes**[ ]  **No**[ ] **20.2 Significant dose response Yes**[ ]  **No**[ ] **20.3 Recommended dose-volume constraint:** |